Form 4: Teladoc Health Executive Mala Murthy Reports Stock Transactions
SEC Form 4
Mala Murthy, Acting CEO and CFO of Teladoc Health, reports the acquisition and disposal of common stock and derivative securities.
Summary
- Mala Murthy, Acting CEO and CFO of Teladoc Health, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On May 31, 2024, Murthy acquired shares through the conversion of performance stock units and restricted stock units.
- Specifically, 2,641 shares were acquired from performance stock units, and 3,369, 2,044, and 7,750 shares were acquired from restricted stock units.
- On June 3, 2024, Murthy sold 8,807 shares at a price of $11.157 per share.
- Following these transactions, Murthy directly owns 78,713 shares of Teladoc Health common stock and various derivative securities including 18,490 performance stock units, 10,107 restricted stock units, 8,176 restricted stock units and 54,254 restricted stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document primarily reports stock transactions, which are common and don't inherently indicate positive or negative sentiment. The sale of shares could be for tax purposes.
Industry Context
Executive stock transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, sales to cover tax obligations are common and may not necessarily reflect a negative outlook.
Stakeholder Impact
- The stock transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the size of the transactions relative to the overall market capitalization of Teladoc Health.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Reporting person was granted 40,426 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 06/01/2022 | Reporting person was granted 24,525 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/03/2023 | Reporting person was granted 93,006 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2024 | The reporting person earned 31,696 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 05/31/2024 | Acquisition of shares through conversion of performance stock units and restricted stock units. |
| 06/03/2024 | Sale of 8,807 shares at $11.157 per share. |
| 06/04/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.